Cannabinoids and products

Medicinal cannabis in New Zealand is a regulated pharmaceutical pathway under the Misuse of Drugs Act, not a general licence to use cannabis. The Medicinal Cannabis Scheme, administered by the Ministry of Health, legalises access through a prescription from a medical practitioner. Products must meet Good Manufacturing Practice (GMP) standards and be approved before they can be supplied. The thing newcomers most often get wrong is that “legal medicinal cannabis” does not mean a patient can legally smoke raw plant material or buy unregulated preparations; the legal form is a manufactured pharmaceutical. Even when dried flower is authorised, it is dispensed through a community chemist, not a dispensary, and patients cannot possess or use it outside the prescription framework.

The scheme is managed by the Medicinal Cannabis Agency (MCA), part of Medsafe, which licences producers and importers and approves items for sale. Under the Misuse of Drugs Act 1975, cannabis remains a controlled drug; the scheme creates a narrow, regulated exception for medical use. It does not legalise recreational use, and it does not allow patients to grow their own plants or buy from unregulated sellers.

What follows explains what those preparations are, how the main cannabinoids differ, and how to navigate the system. It does not rank brands or give doses; that is the job of your prescriber. For detail on specific formats, see the four focused guides: Flower and oils, CBD products, THC products, and Quality and regulation.

Cannabinoids and products: what the law actually permits

The scheme was created by the Misuse of Drugs (Medicinal Cannabis) Amendment Act 2018 and the Misuse of Drugs (Medicinal Cannabis) Regulations 2019, which came into force on 1 April 2020. Under the scheme, a medical practitioner can authorise a manufactured cannabis preparation that meets GMP standards and is approved by the Ministry of Health. The law change did not legalise raw plant material for smoking or make cannabis available without a prescription; it created a legal pathway for patients to access quality-assured pharmaceuticals through a chemist.

The practical implication is that “medicinal cannabis” in New Zealand means a manufactured pharmaceutical, not a herbal remedy. Raw flower is available, but only as a GMP-certified, chemist-dispensed prescription item. This distinction matters because many patients arrive expecting to buy dried plant material over the counter; that is not how the scheme works.

The Medicinal Cannabis Agency licenses cultivators, manufacturers, and suppliers, and maintains a public register of notified preparations. The Misuse of Drugs Act still applies, and possession outside a prescription remains illegal (New Zealand Ministry of Health, 2020; Medicinal Cannabis Agency, 2023).

Urgent cautions

Do not drive or operate heavy machinery after taking any preparation containing THC. Impairment can last for hours, and New Zealand police conduct roadside drug testing. If you experience chest pain, difficulty breathing, severe anxiety, or hallucinations after using a prescribed cannabis medicine, seek urgent medical attention. Report any suspected adverse reaction to your prescriber and to the Centre for Adverse Reactions Monitoring (CARM).

What the active compounds do

Cannabis contains dozens of cannabinoids, but the two that drive most clinical decisions are THC (tetrahydrocannabinol) and CBD (cannabidiol). THC is the compound responsible for the psychoactive effect and is also used for pain, nausea, and appetite stimulation. CBD is non-intoxicating and is prescribed for anxiety, inflammation, and certain seizure disorders. Preparations range from CBD-dominant oils with negligible THC to balanced formulations and high-THC dried flower. The cannabinoid profile, not the product name, determines how an item is regulated, authorised, and dispensed.

How the New Zealand regulatory system works

The Medicinal Cannabis Agency sits within Medsafe and reports to the Ministry of Health. It assesses every medicine against GMP standards before it can be supplied. Prescribers must be registered medical practitioners; they decide whether a patient qualifies and which preparation is appropriate. Pharmacies dispense the prescription, and no other retail channel is legal. The agency also maintains a list of verified medicines, which patients and prescribers can check to confirm a formulation’s regulatory status.

Choosing between formats

The choice between an oil, a capsule, or dried flower turns on onset speed, duration, and the condition being treated. Oils and capsules offer slower, longer-lasting effects and suit chronic conditions. Dried flower, when vaporised, acts faster and is sometimes prescribed for breakthrough pain or nausea. All formats require a prescription, and all are dispensed at a pharmacy. Your prescriber will match the format to your symptoms and monitor your response over time.

Accessing medicinal cannabis: the prescription pathway

A patient cannot self-refer into the scheme. The process starts with a consultation with a registered medical practitioner who is willing to prescribe medicinal cannabis. Not every GP does; some clinics specialise in cannabinoid medicine, and a referral to one of those clinics can be a practical next step when a regular GP declines to prescribe.

During the consultation, the practitioner assesses the patient’s condition, treatment history, and suitability for a cannabis-based medicine. If the practitioner decides a prescription is appropriate, they write it for a specific Ministry of Health-approved preparation. The patient then takes the prescription to a pharmacy, which orders and dispenses the medicine. No other supply route is lawful.

Finding a prescriber

Start by asking your usual GP. If they are unfamiliar with the scheme or unwilling to prescribe, ask for a referral to a clinic that handles medicinal cannabis assessments. The Medicinal Cannabis Agency does not recommend individual practitioners, but its website lists the qualifications and obligations prescribers must meet. Some telehealth services also offer consultations, though they must still comply with New Zealand prescribing standards.

What to bring to the consultation

Bring a summary of your medical history, a list of current and past treatments, and any relevant specialist reports. Be ready to discuss what you have tried, what worked, and what did not. The prescriber needs to establish that conventional options have been inadequate or unsuitable before turning to a cannabis-based medicine. The consultation is not a guarantee of a prescription; it is a clinical assessment.

At the pharmacy

Once you have a prescription, the pharmacy orders the medicine from a licensed supplier. Availability can vary, and some preparations may take days or weeks to arrive. The pharmacy will label the medicine with dosing instructions and store it under secure conditions. You must present identification to collect it, and you cannot transfer it to another person.

Quality, safety, and what GMP means

Every medicinal cannabis preparation supplied in New Zealand must be manufactured under Good Manufacturing Practice standards. GMP is an internationally recognised system that ensures each batch is produced consistently, free from contamination, and accurately labelled for cannabinoid content. The Medicinal Cannabis Agency verifies GMP compliance before a medicine appears on the list of approved preparations.

For patients, GMP means the dose stated on the label is the dose in the bottle. Unregulated cannabis oils or flower bought outside the scheme carry no such assurance. They may contain pesticides, heavy metals, mould, or inaccurate cannabinoid levels. The GMP requirement is the central quality control that separates the legal pathway from the illicit market.

Reading a label

An approved medicine’s label states the concentration of THC and CBD in milligrams per unit or per millilitre, the batch number, the expiry date, and the name of the responsible supplier. Check that the label matches the prescription and that the batch number is legible. If the label is damaged or missing, return the medicine to the pharmacy.

Reporting problems

Any quality concern, such as a broken seal, unusual colour, or unexpected odour, should be reported to the dispensing pharmacy immediately. For suspected adverse reactions, use the CARM reporting form available through the Medsafe website. Reporting helps the agency monitor the safety of medicines on the market and can lead to batch recalls if a pattern emerges.

Travelling with a prescription

Travelling within New Zealand with a prescribed cannabis medicine is legal as long as you carry it in its original labelled container and have a copy of the prescription or a letter from your prescriber. Do not remove the pharmacy label, and do not transfer the medicine to an unmarked container.

International travel is more complicated. Many countries treat cannabis as a prohibited substance regardless of a New Zealand prescription. Before travelling abroad, check the embassy or consulate of your destination country, and any country you will transit through, to confirm their rules. The Ministry of Health advises that taking a medicinal cannabis prescription across international borders carries legal risk, and patients should not assume their New Zealand prescription will be recognised overseas.

What the scheme does not allow

Several activities remain illegal under the Misuse of Drugs Act, even for patients with a prescription. You cannot grow cannabis plants at home, even if you hold a prescription for a cannabis-based medicine. You cannot share, sell, or give your medicine to another person. You cannot import cannabis medicines yourself; all imports must go through a licensed supplier. You cannot use a prescribed medicine in a way that is inconsistent with the prescription, such as smoking dried flower that is labelled for vaporisation.

The scheme also does not require any employer to accommodate cannabis use in the workplace. An employer’s health and safety obligations may restrict the use of impairment-causing medicines, including THC-containing preparations, in safety-sensitive roles. Discuss your prescription with your employer if your work involves driving, operating machinery, or other tasks where impairment creates a risk.

Costs and subsidies

Medicinal cannabis is not subsidised by Pharmac, New Zealand’s pharmaceutical funding agency. Patients pay the full cost of the consultation, the medicine, and any chemist dispensing fees. Prices vary by preparation, dose, and supplier. A CBD-dominant oil may cost less per day than a high-THC dried flower prescription, but the total depends on the prescribed daily amount. Ask the prescriber and the chemist for a cost estimate before starting treatment. Some health insurers cover part of the cost; check your policy for exclusions and annual limits.

Staying informed

The Medicinal Cannabis Agency updates its public register of approved medicines, prescriber guidance, and regulatory notices regularly. Check the Ministry of Health website for the current list of verified preparations and for any changes to the prescribing rules. The scheme is still evolving, and new medicines, licence categories, and clinical guidance appear as the evidence base grows.